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Background: This study investigated treatment adherence among people with recent injecting 
drug use in a study of sofosbuvir/velpatasvir therapy for HCV infection. Methods: SIMPLIFY is 
an international open-label, single-arm multicentre study that recruited participants with recent 
injecting drug use (previous six months) and chronic HCV genotype (G) 1-6 infection between 
March and October, 2016 in seven countries (19 sites). Participants received 
sofosbuvir/velpatasvir once-daily for 12 weeks administered in a one-week electronic blister pack 
(records the time and date of each dose) for 12 weeks. We evaluated non-adherence (<90% 
adherent) as measured by electronic blister-pack assessed using logistic regression and generalised 
estimating equations (continuous) with detailed analyses of dosing dynamics. Results: Among 
103 participants, 97% (n=100) completed treatment. Median adherence to therapy was 94%. 
Overall, 32% (n=33) were considered non-adherent (<90% adherence). Adherence significantly 
decreased over the course of therapy. Recent stimulant injecting (cocaine and/or amphetamines) at 
treatment initiation and during treatment was independently associated with non-adherence. 
Inconsistent dose timing (standard deviation of daily dose timing of ≥240 minutes) was also 
independently associated with non-adherence to therapy. Factors associated with inconsistent dose 
timing included lower levels of education and recent stimulant injecting. SVR was similar among 
adherent and non-adherent populations (94% vs. 94%, P=0.944). Conclusion: This study 
demonstrated high adherence to once-daily sofosbuvir/velpatasvir therapy among a population of 
people with recent injecting drug use. Recent stimulant injecting prior to and during DAA therapy 
and inconsistent dose-timing during treatment was associated with non-adherence. However, there 
was no impact of non-adherence on response to therapy, suggesting that adherence is not a 






There is a significant burden of hepatitis C virus (HCV) infection among people who inject drugs 
(PWID) globally [1]. The World Health Organization has set a goal to eliminate HCV as a major 
global public health concern by 2030. Between 2015 and 2030, targets include reducing new 
infections by 80%, reducing HCV deaths by 65%, increasing HCV diagnoses from <20% to 90%, 
and increasing the number of eligible persons receiving treatment from <10% to 80% [2]. Given 
that 23% of new HCV infections occur among recent PWID globally [3], scale up of HCV therapy 
will be required among this population to achieve HCV elimination targets in many countries. 
While HCV therapy has been demonstrated to be safe and effective in PWID [4], some countries 
including certain states in the United States and a number of European countries continue to 
withhold HCV therapy from people with ongoing injecting drug use. These restrictions are 
implemented at the level of government policy for the reimbursement of HCV DAA therapies and 
are based in part on concerns of poor adherence to therapy [5-7].  
 
Studies in the interferon era demonstrated that treatment completion and adherence among recent 
PWID is comparable to people without recent injecting drug use [8, 9].[8, 9]. In the era of direct 
acting antiviral (DAA) therapy, studies have demonstrated that adherence to DAA therapy is high 
among people receiving opioid substitution therapy (OST) [10-15].[10-15]. However, there are 
limited data on adherence to DAA therapy among people with recent injecting drug use [4]. 
Further data is needed to fully understand HCV treatment adherence in the DAA era among recent 
PWID, including the evaluation of daily dosing dynamics and factors associated with adherence 
among people with recent injecting drug use. 
 
SIMPLIFY is an international multicentre, open-label phase 4 trial evaluating the efficacy and 




patients infected with HCV genotypes 1 through 4 with recent injecting drug use (in the last six 
months). Overall, 96%The primary study analysis demonstrated that 96% of the population 
completed therapy, the median adherence was 94% and the proportion who achieved SVR was 
94% [16].  
 
The aims of this analysis from the SIMPLIFY study were to further evaluate adherence to HCV 
DAA therapy and associated factors among PWID, evaluate dosing dynamics including 
consistency of dose timing and the change in adherence over the course of therapy, and compare 





Study design and participants 
In this international, multicentre, open-label phase 4 trial, we enrolled participants from 19 sites, 
in Australia (seven sites), Canada (six sites), New Zealand (one site), Norway (one site), 
Switzerland (two sites), the UK (one site), and the USA (one site). We recruited people from three 
drug treatment clinics, 12 hospital clinics, a private practice, and three community clinics [17]. 
 
Participants had to be >18 years of age, have chronic HCV genotypes 1-6 (but no patients with 
genotype 5 or 6 were enrolled), be naïve to NS5A-based HCV therapy, and have recent injecting 
drug use (self-reported injecting drug use within six months of enrolment). Participants with HIV 
infection and/or decompensated liver disease were excluded. Full eligibility criteria are provided 
in the study protocol as previously published [16]. 
 
All participants gave written informed consent before study procedures started. The study protocol 
was approved by St Vincent’s Hospital, Sydney Human Research Ethics Committee (primary 
study committee), and local ethics committees at all study sites, and was done according to the 
Declaration of Helsinki and International Conference on Harmonisation Good Clinical Practice 
guidelines. An independent data and safety monitoring board reviewed the progress of the study. 
 
Procedures 
Patients received a fixed-dose combination tablet containing 400 mg of sofosbuvir and 100 mg of 
velpatasvir, administered orally once daily for 12 weeks. Participants received all study drugs 
weekly in an electronic blister pack (Information Mediary Corporation, Ottawa, Canada) with an 
integrated sensor grid that recorded the time and date that each daily dose was punched out of the 




same daily dosing interval and if a dose was missed to take the dose as soon as possible on the 
same day. In cases of a missed day of treatment, participants were instructed not to double the 
next dose. Participants were given the equivalent of AUS$10 as an incentive to return the blister 
pack. Once the packs were returned, a specific reader was used to download data on adherence. In 
addition to blister-pack measurement, adherence was also measured by counting any pills 
remaining in the blister-pack when returned and through the completion of a self-reported 
adherence questionnaire every four weeks to record the number of missed doses in the last 28 
days. and the patient-reported reasons for missed doses.  
 
We assessed participants at screening, enrolment (baseline), weeks 2, 4, 8, and 12 (end) of 
therapy, and at weeks 16 (SVR4), 24 (SVR12), and 36 (SVR24) after the beginning of treatment. 
Participants also visited the study site weekly to receive their medication in the electronic blister 
pack. Study nurses and physicians provided services to reduce risk and harm (eg, access to sterile 
syringes, other injecting equipment, and opioid substitution therapy) as per standard of care in 
their country. 
 
Participants completed a self-administered questionnaire on a tablet computer at enrolment,  
baseline (start of treatment), every fourth week during treatment, and at 12 weeks after completing 
treatment. Participants received the equivalent of AUS$20 for their time and expenses. The 
questionnaires collected information on demographics (age, sex, ethnicity, employment status, 
education level, and housing status), drug and alcohol use, injecting risk behaviours, drug 
treatment, and health utility. To assess alcohol consumption, we used the Alcohol Use Disorders 
Identification Test–Consumption, which is derived from the first three questions of the full test; 
scores of 3 or more (women) and 4 or more (men) indicate hazardous consumption or active 






The primary outcome of this analysis was treatment non-adherence, as measured by receiving 
<90% of doses to a maximum of one dose per day. consistent with previous studies into 
medication adherence [18, 19]. A secondary endpoint analysed in this study was inconsistent dose 
timing, as measured by a standard deviation of daily dose timing of ≥240 minutes and ongoing 
daily adherence. 
 
Daily adherence was measured by electronic blister-packs which recorded the date and time each 
dose of sofosbuvir/velpatasvir was removed. Each day was assigned 0 if no doses were removed 
from the blister-pack or was assigned 1 if at least one dose was removed from the blister-pack on 
an individual day of therapy. On days where more than one dose was removed, participants were 
assigned an adherence of 1 for the day. 
 
Weekly adherence to sofosbuvir/velpatasvir was calculated as the number of doses removed from 
a blister-pack in a given treatment week (to a maximum of seven) divided by seven days.  
 
Overall adherence was calculated by dividing the number of total doses removed from the blister-
pack (to a maximum of one per day) by the total number of expected doses (84 doses). Among 
individuals in whom therapy was extended, adherence was calculated as the proportion of 
expected doses received in the first 84 days of therapy. In the case of a damaged blister-pack from 
which data could not be retrieved, clinical pill count data was used. 
 
Self-reported overall adherence to sofosbuvir/velpatasvir therapy was calculated by subtracting the 




over 84 days) from the total expected number of doses (n=84). The number of reported doses was 
then divided by the total expected number of doses (n=84). 
 
Inconsistent dose timing was determined by calculating the standard deviation in daily dose timing 
in minutes. The standard deviation of dose timing for each participant was then stratified by <240 




Daily blister-pack was assessed and the proportion of participants with overall adherence of <90% 
was calculated. Participants with <90% and ≥90% adherence were compared using Chi-square or 
Fisher’s exact test, as appropriate.  
 
Logistic regression was used to assess baseline predictors of <90% adherence (non-adherence) and 
dosing consistency. Factors hypothesised to be predictive of non-adherence and inconsistent dose 
timing were determined based on factors previously shown or hypothesised to be associated with 
adherence to HCV therapy. These predictors included age (stratified by median), sex, education, 
hazardous alcohol consumption at baseline, current OST at baseline, recent (past month) injecting 
drug use at baseline, recent heroin injecting at baseline, recent cocaine injecting at baseline, recent 
amphetamine injecting at baseline, recent stimulant (cocaine and/or amphetamine) injecting at 
baseline, and frequency of injecting drug use at baseline. Unadjusted logistic regression analyses 
were performed to estimate odds ratios (OR) and corresponding 95% confidence intervals (95% 
CI) to identify predictors of an overall adherence of <90% and inconsistent dose timing. All 
variables with p<0.20 in the unadjusted analyses were considered for multivariate logistic 




result of a likelihood ratio test. Odds ratios and corresponding 95% confidence intervals were 
generated to identify on-treatment behavioural predictors of an overall adherence of <90%. 
 
Logistic regression was also used to assess on-treatment behavioural factors associated with non-
adherence. On-treatment behavioural factors hypothesised to be associated with non-adherence 
included hazardous alcohol consumption on treatment, OST on treatment, any injecting drug use 
on treatment, any heroin injecting on treatment, any cocaine injecting on treatment, any 
amphetamine injecting on treatment, any stimulant (cocaine and/or amphetamine) injecting on 
treatment, average dose timing on treatment, and consistency of dose timing on treatment. 
Unadjusted logistic regression analyses were performed to identify factors associated with an 
overall adherence of <90%. All variables with p<0.20 in the unadjusted analyses were considered 
for multivariate logistic regression models using a backward stepwise approach as above.  
 
Generalised estimating equation (GEE) analyses were used to investigate the change in adherence 
over the course of therapy and the impact of on-treatment behavioural factors on treatment 
adherence. GEE methods were used to account for the correlated nature of repeated measurements 
among individual participants and to provide a detailed time-updated analysis of ongoing 
treatment adherence. The impact of time on treatment was assessed by including day of treatment 
as a factor in GEE analyses with the effect reported per study week. On-treatment behavioural 
factors hypothesised to be associated with non-adherence included hazardous alcohol consumption 
on treatment, OST on treatment, any injecting drug use on treatment, any heroin injecting on 
treatment, any cocaine injecting on treatment, any amphetamine injecting on treatment, any 
stimulant injecting on treatment, and treatment duration. GEE models were specified using a 




variables with p<0.20 in the unadjusted analyses were considered for multivariate logistic 
regression models using a backward stepwise approach as above. 
 
Statistically significant differences were assessed at p<0.05; p values are two-sided. All analyses 
were performed using the statistical package Stata v14.1 (College Station, TX, United States). 
 
Role of the funding source 
The study (including study medications) was funded by a research grant from Gilead Sciences. 
The sponsor (The Kirby Institute, UNSW Sydney) designed the study, collected the data, managed 







Overall, 103 participants were enrolled in the study and initiated HCV therapy. The baseline 
demographic and behavioural characteristics of the participants are shown in Table 1. The median 
age was 48 years, 72% were male, and 48% reported an education level of high school or greater.  
 
Fifty-six percent of participants were receiving OST at baseline and 74% reported injecting drug 
use in the last month. Twelve percent of participants neither injected drugs in the last month nor 
were receiving OST at baseline. The drugs most commonly injected in the month prior to 
commencement of therapy were heroin (55%) and amphetamines (30%; Table 1). 
 
Treatment completion, adherence, and dosing patterns 
Overall, 97% (n=100) of participants completed treatment (Table 2). Reasons for not completing 
treatment were loss to follow-up (n=2) and death due to overdose (n=1).  
 
The overall daily blister-pack adherence was 94% (IQR 88-98%; Table 2 and Figure 1). 
Adherence was higher when measured by weekly blister-pack adherence (98%, IQR 94-100%) 
and self-reported adherence (99%, IQR 98-100%; Table 2 and Figure 2). Patient reported reasons 
for non-adherence were available in 81 instances over the course of therapy and included “Forgot” 
(n=54, 67%), “Inaccessible at time of dose” (n=14, 17%), “Lost pill(s)” (n=7, 9%), and “Other” 
(n=6, 7%). There were five instances of a damaged blister-pack from which electronic adherence 
data could not be obtained. In all cases of damaged blister-packs, no pills remained in the returned 
blister-pack and therefore these days with missing adherence data were counted as doses received. 
One participant had no available blister-pack data due to being lost to follow-up before the return 





By daily blister-pack measurement, the majority of participants missed at least one daily dose with 
88% missing at least one dose of scheduled therapy. The majority (54%) of participants missed 
between one and eight daily doses of sofosbuvir/velpatasvir therapy (Table 2) and 54% of 
participants missed no more than one consecutive day of therapy.  Eleven participants had at least 
one episode of nonadherence for ≥7 consecutive days with one participant having two episodes of 
nonadherence for ≥7 consecutive days. These episodes of nonadherence of ≥7 days occurred in 
four participants (4%) in the first six weeks of therapy and in eight participants (8%) in the last 6 
weeks of therapy. Individual examples of adherent and non-adherent participant’s dosing patterns 
are shown in Figure 3a and 3b respectively. 
 
Daily dose timing as collected by electronic blister-pack was tabulated to determine the average 
time of day during which participants took their dose (Table 2). The majority of participants, on 
average, took their daily dose in the morning or afternoon (5:00 AM–11:59 AM, 41%; 12:00 PM-
4:59 PM; 82, 41%). Daily dose timing was inconsistent, with only 24% (24 of 102) of participants 
with available blister-pack data demonstrating a standard deviation in dose time of less than 120 
minutes. Daily blister-pack adherence of ≥90% was reported in 100% (24 of 24), 77% (33 of 43), 
and 31% (11 of 35) of those with a standard deviation in dose time of less than 120 minutes, 120-
240 minutes, and ≥240 minutes respectively.  
Baseline predictors of overall blister-pack adherence 
The proportion of participants with <90% blister-pack adherence stratified by key behavioural and 
demographic characteristics is shown in Table 3. In unadjusted logistic regression analyses, the 
only baseline factor that was associated with non-adherence to therapy was injecting stimulants 





On-treatment behavioural predictors of overall blister-pack adherence 
The proportion of participants with <90% blister-pack adherence stratified by key on-treatment 
behavioural characteristics is shown in Table 4. In unadjusted logistic regression analyses, on-
treatment behavioural factors that were associated with non-adherence to therapy included 
amphetamine injecting during treatment, stimulant injecting during treatment, and a standard 
deviation of dose timing of ≥240 minutes. In adjusted analyses, behavioural factors which were 
associated with non-adherence to therapy were stimulant injecting on treatment (adjusted odds 
ratio [aOR] 3.33, P=0.023), and a standard deviation of dose timing of ≥240 minutes (aOR 12.57, 
P<0.001; Table 4).  
 
In GEE analyses past month stimulant injecting during treatment remained associated with daily 
nonadherence to therapy (aOR 2.13, P<0.001). Past month heroin injecting was also associated 
with daily nonadherence to therapy (aOR 1.78, P<0.001) in GEE analyses (Supplementary table 
1). 
 
Change in adherence over the course of therapy 
Change in adherence over the course of therapy is illustrated in Figures 2 and 4. In GEE analyses, 
later study visit was associated with non-adherence to therapy (per week; aOR 1.08, P<0.001; 
Supplementary table 1).  
 
Baseline predictors of inconsistent dose timing 
The proportion of participants with blister-pack data with a standard deviation of dose timing of 




In unadjusted analyses participants with less than high school education were more likely to take 
their dose at inconsistent times. In adjusted analyses, baseline factors which were associated with 
inconsistent dose timing were less than high school education (aOR 2.77, P=0.025) and recent 
stimulant injecting (aOR 2.43, P=0.048; Supplementary Table 2). 
 
Impact of DAA adherence on sustained virologic response 
There were no cases of virological failure or virological relapse among participants in this study 
[16]. There was no difference in SVR among those with sofosbuvir/velpatasvir adherence ≥90% 
(94%, 66 of 70) as compared to those with sofosbuvir/velpatasvir adherence of <90% (94%, 31 of 
33, P=0.944). There was also no statistically significant difference in the proportion achieving 
SVR between those with (93%, 85 of 91) and without missed doses during therapy (100%, 12 of 
12, P=0.359). However, compared to the proportion with SVR in those patients who received all 
12 weeks of therapy (9897%, 97 of 99100), participants who did not complete therapy (0%, 0 of 
43) had a significantly lower likelihood of achieving SVR due to loss to follow-up or death 
(P<0.001). Of the 11 participants with at least one episode of nonadherence for ≥7 consecutive 






This study investigated adherence to once-daily sofosbuvir/velpatasvir therapy for HCV infection 
among a cohort of people with recent injecting drug use. A high adherence to therapy was 
observed overall, but treatment adherence declined during therapy. Recent stimulant injecting at 
the time of treatment initiation was associated with non-adherence to therapy. During treatment, 
stimulant injecting and inconsistent dose timing were associated with non-adherence. Adherence 
did not impact response to therapy. These data demonstrate that adherence to HCV DAA therapy 
among PWID can occur concurrently with ongoing injecting drug use. However, recent stimulant 
injecting prior to and during therapy was associated with non-adherence to therapy.  
 
The overall median adherence to sofosbuvir/velpatasvir was high at 94%.% as measured by 
electronic blister pack with higher adherence as measured by self-report, consistent with a recent 
study of HCV DAA therapy which monitored adherence using measured using medication event 
monitoring system (MEMS) caps [20]. However, 88% of participants missed at least one dose of 
therapy, with the majority only missing between one and eight doses. The adherence observed in 
this study is higher than adherence observed in studies of interferon-based therapies among PWID 
[9, 18][9, 21] and similar to what has been observed in previous studies of HCV DAA therapy 
among people receiving OST [19-24].[20, 22-26]. This similarity was observed despite the strict 
definition of adherence used in this study based on data collection using an electronic blister-pack. 
It is likely that the weekly contact with healthcare providers and the use of a blister-pack for the 
administration of therapy may have assisted with improving adherence. However, despite 
imperfect daily adherence and the inconsistent adherence patterns observed, treatment completion 
and response to therapy was high with 96% of participants completing therapy and 94% of all 
participants achieving an SVR with no virological failures [16]. All treatment failures were due to 




participants who completed treatment and attended their SVR12 visit achieved an SVR. There was 
no impact of non-adherence on SVR. Episodes of non-adherence of ≥7 consecutive days which 
occurred in 11 participants did not impact the proportion achieving SVR. These data suggests that 
once-daily sofosbuvir/velpatasvir is a robust regimen with some forgiveness in terms of the level 
of adherence required to achieve an SVR.  
  
Recent stimulant injecting prior to and during treatment was associated with non-adherence to 
therapy. Although previous studies in the interferon era demonstrated that recent injecting drug 
use at baseline was not associated with reduced adherence to HCV therapy [8, 9, 23, 25-32][8, 9, 
25, 27-34] or treatment completion [9, 25, 27, 33][9, 27, 29, 35], many of these studies were 
limited by small sample sizes, were conducted at a single centre, and were retrospective (without 
standardized collection of drug use data). More recent studies conducted in the DAA era have 
demonstrated an association between recent drug use and reduced adherence to HCV therapy in 
people with a history of injecting drug use [22, 24].[20, 26]. This study of people with recent 
injecting drug use is consistent with these findings and provides novel data to demonstrate that the 
type of drug injected, specifically stimulants, may have an impact on adherence to DAA therapy 
among recent PWID. Although non-adherence did not impact SVR in this study, interventions to 
improve adherence may be needed in the context of shortened treatment where the impact of non-
adherence may be amplified.  
 
Very little is known about the dosing dynamics of HCV treatment among PWID. In this study, 
electronic blister-pack monitoring of therapy allowed for detailed analysis of dosing dynamics 
including episodes of nonadherence, dose timing and the consistency of dose timing. Analyses of 
episodes of nonadherence demonstrated that consecutive missed doses were common with 46% of 




participants missing at least seven consecutive days of therapy. The method of evaluating 
adherence to HCV therapy using an electronic blister pack is novel, providing considerable insight 
into adherence in this setting and may have applications in other settings (for HCV treatment and 
adherence to therapies for other conditions). Given the lack of virologic failure in this study it is 
apparent that these brief episodes of non-adherence did not impact SVR. Further, even among 
people with >7 consecutive missed doses, there were no cases of virological relapse or non-
response. Further research is needed to fully understand the impact of missed doses of therapy 
(particularly extended periods of missed doses) on treatment outcomes and to determine the 
threshold at which SVR is hampered.  
 
In logistic regression analyses participants with inconsistent dose timing were more likely to be 
non-adherent to therapy. Lower education levels and recent stimulant injecting were found to be 
associated with inconsistent dose timing. Similar to the analysis of factors associated with non-
adherence, this finding suggests that interventions to enhance treatment adherence among 
participants with stimulant injecting may be needed. In particular, interventions which aid in 
consistent dose timing among this population could be beneficial. However, the improved 
adherence among the group with consistent dose timing may have been a result of unmeasured 
factors and therefore further research is needed to understand if interventions to improve 
consistency in dose timing could result in improved adherence. 
 
The measurement of adherence by electronic blister-pack also allowed for a detailed investigation 
of the change in adherence over the course of therapy. Later time points during therapy were 
independently associated with reduced daily adherence, consistent with a recent study of inner-
city patients in the United States which demonstrated a decrease in adherence to DAA therapy 




there have been a number of recent studies investigating shortened HCV DAA therapy [34-
36].[36-38]. This finding of decreased treatment adherence over the course of therapy suggests 
that these efforts to shorten therapy could potentially result in increased overall treatment 
adherence among PWID.  
  
This study had some limitations. Despite the robust measurement of treatment adherence using 
electronic blister-packs to record the date and time of doses, this measurement relied on the 
accurate usage of the device. In some instances, multiple pills were removed on one day followed 
by missed doses on subsequent days. By daily blister-pack adherence, this would have only 
counted as one dose given that dosing is meant to be daily. If the previously removed pill was 
taken on a subsequent day, this dose would not be recorded by the blister-pack. As a result, daily 
blister-pack adherence likely represents an underestimation of the true adherence to therapy. 
Conversely, weekly blister-pack adherence assumes that the patient took all pills removed in a 
given week when this may not be the case (e.g. multiple pills removed on the last day of the week 
before the blister-pack was retuned). As a result, weekly blister-pack adherence likely 
overestimates the true treatment adherence. Thus, true adherence probably exists somewhere 
between daily and weekly blister-pack measurements. Despite this, daily blister-pack 
measurement is a significantly more robust method for measuring adherence when compared to 
clinical pill count or self-report and provides interesting insights into the dosing dynamics of 
PWID. Although SIMPLIFY is an international study, these results cannot necessarily be 
generalised to the wider PWID population. Patients were treated at hospital-based HCV clinics, 
community-based drug treatment clinics, and community health centres experienced in HCV care 
in PWID. Furthermore, HIV-infected people were excluded from this study and the study 
population consisted of a high proportion of people on OST. As such, patients recruited into this 




services and is not necessarily generalisable to treatment in other settings. or among populations 
with a differing prevalence of OST. These results also cannot necessarily be generalised to other 
DAA regimens which may require more complex dosing or increased pill burden and may have a 
lower barrier to resistance. Lastly, treatment adherence is a highly complex phenomenon that may 
be influenced by a number of unmeasured factors including the effect of close monitoring of 
adherence, as was done in this trial. Further, although the incentive given for return of the blister 
pack was not directly tied to a participant’s adherence, this incentive may have indirectly 
encouraged greater adherence to therapy. Despite these limitations this study represents a highly 
detailed and robust investigation of treatment adherence among a population of PWID with recent 
injecting drug use. 
 
Despite intermittent and consecutive days of nonadherence, SVR remained high with no cases of 
virological failure or viral relapse, demonstrating that there is some forgiveness with a regimen of 
once- daily sofosbuvir/velpatasvir [16]. However, further research is needed to investigate the 
impact of adherence to HCV DAA therapies on response to therapy in larger, more diverse studies 
of recent PWID and with other HCV regimens. Taken together, these data support the inclusion of 





Declaration of Interests 
JG reports grants and personal fees from AbbVie, Cepheid, Gilead Sciences, and Merck. OD 
reports grants from Gilead Sciences during this study and grants from Gilead Sciences, Merck, 
and AbbVie. PB reports grants and personal fees from AbbVie, Bristol-Myers Squibb, Gilead 
Sciences, and Merck Sharp & Dohme. MH reports grants from Gilead Sciences, Bristol-Myers 
Squibb, and AbbVie. JBr reports consultant fees from Gilead Sciences and Merck. AHL 
reports grants and personal fees from Gilead Sciences and Merck. GVM reports grants and 
personal fees from Gilead Sciences and grants from AbbVie. JP reports personal fees from 
Janssen and Genetech. CC reports grants and personal fees from Gilead Sciences. JJF reports 
grants and personal fees from AbbVie, Merck, Gilead Sciences, and Janssen, personal fees 
from Contravir, and grants from Abbott. CF reports grants and non-financial support from 
Kirby Institute during this study and grants from Gilead Sciences, ViiV HealthCare, and 
Merck. GJD reports grants, personal fees, and non-financial support from AbbVie, Merck, 
Bristol-Myers Squibb, and Roche; grants and personal fees from Janssen; personal fees and 
non-financial support from Gilead Sciences; and personal fees from GlaxoSmithKline and 
Abbott Diagnostics. PR reports fees for educational talks from Gilead Sciences, Merck Sharp 
& Dohme, and AbbVie, and is on the advisory board for Merck Sharp & Dohme. BC reports 
grants, personal fees, and non-financial support from Gilead Sciences, Merck, and AbbVie. EG 
reports personal fees from being a Clinical Advisor for Gilead Sciences, Merck, Janssen, and 
AbbVie, and personal fees from Gilead Sciences Speaker Bureau and AbbVie Speaker Bureau. 
JFD reports grants and personal fees from Gilead, Merck Sharp & Dohme, Janssen, and 






We thank the study participants, researchers, and staff for their contribution to the research. We 
also thank Diana Brainard, John McHutchison, and others at Gilead Sciences for their support. 
This work was supported by funding from Gilead Sciences. The Kirby Institute, which 
sponsored this study, is funded by the Australian Government Department of Health and 
Ageing. The views expressed in this publication do not necessarily represent the position of the 
Australian Government. EBC holds a UNSW Sydney Tuition Fee Scholarship. JG is supported 
by a National Health and Medical Research Council Career Development Fellowship. GJD is 
supported by a National Health and Medical Research Council Practitioner Research 
Fellowship. BH is supported by a National Health and Medical Research Council Early Career 
Fellowship. JG, GVM, and GJD have received funding from the US National Institute on Drug 




Table 1: Participant baseline characteristics of all participants in the SIMPLIFY study 
Characteristic, n (%) Overall (n=103) 
Age, median (25%, 75%) 48 (41, 53) 
Male sex 74 (72) 
High school or greater education 49 (48) 
Any injecting drug use in the last month  
 
    Heroin 57 (55) 
    Cocaine 13 (13) 
    Amphetamines 31 (30) 
Any poly-drug injecting in the last month 40 (39) 
    Heroin and stimulant 15 (15) 
Single drug injecting in the last month  
    Only heroin 24 (23) 
    Only cocaine 3 (3) 
    Only amphetamines 10 (10) 
Injecting drug use frequency in the last month  
 
    Never 27 (26) 
    <daily 49 (48) 
    >daily 27 (26) 
Opioid substitution treatment (ever) 84 (82) 
OST and recent injecting (past month) at baseline 
 
    No OST, no recent injecting 12 (12) 
    No OST, recent injecting 33 (32) 
    OST, no recent injecting 15 (15) 
    OST, recent injecting 43 (42) 
Study site distribution 
 
    Australia/New Zealand  43 (42) 
    North America  40 (39) 











Treatment completion 100 (97) 
Missed doses of sofosbuvir/velpatasvir as measured by 
electronic blister-pack, n (%)  
    No missed doses (100%) 12 (12) 
    1-4 missed doses (95-<100%) 36 (35) 
    5-8 missed doses (90-<95%) 20 (19) 
    9-17 missed doses (80-<90%) 17 (17) 
    ≥18 missed doses (<80%) 18 (17) 
Longest episode of non-adherence*  
    1 day 44 (43) 
    2 days 19 (18) 
    3 days 3 (3) 
    4 days 9 (9) 
    5 days 2 (2) 
    6 days 3 (3) 
    ≥7 days 11 (11) 
Median on-treatment sofosbuvir/velpatasvir adherence 
percent  
    Patient report 99 (98-100) 
    Blister-pack, weekly 98 (94-100) 
    Blister-pack, daily 94 (88-98) 
Dose timing* 
 
    Morning (5:00AM-11:59AM) 42 (41) 
    Afternoon (12:00PM-4:59PM) 42 (41) 
    Evening (5:00PM-12:00AM) 17 (17) 
    Night (12:00AM-4:59AM) 1 (1) 
Consistency in dose timing (standard deviation in 
minutes)*  
    <120 24 (24) 
    ≥ 120-<240 43 (42) 
    ≥ 240 35 (34) 




Table 3: Unadjusted baseline factors associated with overall treatment adherence of <90% 
among all participants in the SIMPLIFY study (n=103). 
  
Sofosbuvir/velpatasvir 









OR (95% CI) P 
Age (years) 
   
   ≤41 17 (61) 11 (39) 1.00 - 
   >41 53 (71) 22 (29) 0.64 (0.26-1.59) 0.337 
Gender 
    
   Female 23 (79) 6 (21) 1.00 - 
   Male 47 (64) 27 (36) 0.45 (0.16-1.25) 0.128 
Education 
    
   <High school 37 (70) 16 (30) 1.00 - 
   High school or greater 33 (66) 17 (34) 1.19 (0.52-2.73) 0.679 
Hazardous alcohol consumption 
  
   No 56 (66) 29 (34) 1.00 - 
   Yes 14 (78) 4 (22) 0.55 (0.17-1.83) 0.331 
Current OST 
   
   No 32 (71) 13 (29) 1.00 - 
   Yes 38 (66) 20 (34) 1.30 (0.56-3.01) 0.547 
Injecting (last month) 
   
   No 20 (74) 7 (26) 1.00 - 
   Yes 50 (66) 26 (34) 1.49 (0.56-3.97) 0.430 
Frequency of injecting (last month) 
  
   Never 20 (74) 7 (26) 1.00 - 
   Less than daily 31 (63) 18 (37) 1.66 (0.59-4.69) 0.339 
   Daily or greater 19 (70) 8 (30) 1.20 (0.36-3.97) 0.761 
Heroin injecting (last month) 
  
   No 33 (72) 13 (28) 1.00 - 
   Yes 37 (65) 20 (35) 1.37 (0.59-3.18) 0.461 
Cocaine injecting (last month) 
  
   No 64 (71) 26 (29) 1.00 - 
   Yes 6 (46) 7 (54) 2.87 (0.88-9.36) 0.080 
Amphetamine injecting (last month) 
 
   No 53 (74) 19 (26) 1.00 - 
   Yes 17 (55) 14 (45) 2.30 (0.95-5.54) 0.064 
Stimulant injecting (last month) 
 
   No 47 (77) 14 (23) 1.00 - 
   Yes 23 (55) 19 (45) 2.77 (1.18-6.50) 0.019 
a 




Table 4: Unadjusted and adjusted analysis of on-treatment factors associated with overall treatment adherence of <90% among all participants in the 
SIMPLIFY study (n=103). 
 
Sofosbuvir/velpatasvir 









OR (95% CI) P aOR  (95% CI) P 
Hazardous alcohol consumption while on treatment 
 
     No 53 (65) 29 (35) 1.00 - - - 
   Yes 17 (81) 4 (19) 0.43 (0.13-1.40) 0.161 - - 
OST while on treatment 
   
    No 33 (80) 8 (20) 1.00 - - - 
   Yes 37 (62) 23 (38) 2.56 (1.01-6.51) 0.048 - - 
Injecting while on treatment 
  
     No 12 (67) 6 (33) 1.00 - - - 
   Yes 58 (70) 25 (30) 0.86 (0.29-2.55) 0.789 - - 
Heroin injecting while on treatment 
  
     No 33 (75) 11 (25) 1.00 - - - 
   Yes 37 (65) 20 (35) 1.62 (0.68-3.88) 0.278 - - 
Cocaine injecting while on treatment 
 
     No 62 (71) 25 (29) 1.00 - - - 
   Yes 8 (57) 6 (43) 1.86 (0.59-5.91) 0.293 - - 
Amphetamine injecting while on treatment 
 
     No 51 (77) 15 (23) 1.00 - - - 
   Yes 19 (54) 16 (46) 2.86 (1.19-6.90) 0.019 - - 
Stimulant injecting while on treatment 
 
     No 44 (80) 11 (20) 1.00 - - - 
   Yes 26 (57) 20 (43) 3.01 (1.27-7.14) 0.012 3.39 (1.19-9.67) 0.023 
Dose timing (average) 
   
      Morning (5:00AM-11:59AM) 31 (74) 11 (26) 1.00 - - - 
    Afternoon (12:00PM-4:59AM) 25 (60) 17 (40) 2.11 (0.84-5.30) 0.842 - - 
    Evening (5:00PM-12:00AM) 13 (76) 4 (24) 0.87 (0.23-3.23) 0.832 - - 
    Night (12:00AM-4:59AM) 1 (100) 0 (0) * * - - 
Consistency in dose timing (standard deviation in minutes) 
      <240 12 (34) 23 (66) 1.00 - - - 
    ≥ 240 58 (87) 9 (13) 12.35 (4.59-33.24) <0.001 12.44 (4.37-35.41) <0.001 
 a 




Figure 1: Daily adherence to sofosbuvir/velpatasvir therapy as measured by weekly-
administered electronic blister-packs. Rows represent individual participants and columns 
represent days of therapy. Green boxes represent a dose received, with light green boxes 
indicating a damaged blister-pack where clinical pill count data was used. Yellow boxes 
represent no dose received on that treatment day and white boxes represent early treatment 




Figure 2: Mean 4-weekly treatment adherence over time stratified by self-reported adherence 





Figure 3: Examples of daily adherence to treatment among four adherent (>=90%) participants (a) and four nonadherent (<90%) participants (b). 
All patients achieved SVR. 




Figure 4: Mean daily treatment adherence to sofosbuvir/velpatasvir therapy over the 84 day 





Supplementary table 1: GEE analysis of factors associated with daily non-adherence to therapy 
as measured by electronic blister-pack among all participants in the SIMPLIFY study with 





95% CI P 
Adjusted 
OR  
95% CI P 
Hazardous alcohol consumption 
    
   No 1.00 - - - - - 
   Yes 1.43 0.92-2.24 0.113 - - - 
Current OST 
     
   No 1.00 - - - - - 
   Yes 1.11 0.79-1.56 0.544 - - - 
Injecting (last month) 
     
   No 1.00 - - - - - 
   Yes 1.57 1.17-2.11 0.002 - - - 
Frequency of injecting (last month) 
    
   Never 1.00 - - - - - 
   Less than daily 1.56 1.16-2.10 0.003 - - - 
   Daily or greater 1.68 1.09-2.60 0.019 - - - 
Heroin injecting (last month) 
    
   No 1.00 - - - - - 
   Yes 1.44 1.10-1.89 0.008 1.78 1.34-2.35 <0.001 
Cocaine injecting (last month) 
    
   No 1.00 - - - - - 
   Yes 0.91 0.56-1.49 0.719 - - - 
Amphetamine injecting (last month) 
    
   No 1.00 - - - - - 
   Yes 1.97 1.48-2.62 <0.001 - - - 
Cocaine or amphetamine injecting (last month) 
   
   No 1.00 - - - - - 
   Yes 2.07 1.57-2.74 <0.001 2.13 1.62-2.81 <0.001 
Time since treatment initiation 
     




Supplementary table 2: Unadjusted and adjusted analysis of baseline factors associated with a standard deviation of dose timing of ≥240 minutes 
among all participants in the SIMPLIFY study with available blister-pack data (n=102). 
  
Standard deviation of dose timing 
of <240 minutes (%; n=67) a 
Standard deviation of dose timing 
of ≥240 minutes (%; n=35) a 
OR (95% CI) P aOR (95% CI) P 
Age (years)   
     
   ≤41 14 (52) 13 (48) 1.00 - - - 
   >41 53 (71) 22 (29) 0.45 (0.18-1.10) 0.081 - - 
Gender 
      
   Female 49 (67) 24 (33) 1.00 - - - 
   Male 18 (62) 11 (38) 1.25 (0.51-3.05) 0.628 - - 
Education 
      
   High school or greater 37 (76) 12 (24) 1.00 - - - 
   <High school 30 (57) 23 (43) 2.36 (1.01-5.52) 0.047 2.77 (1.14-6.72) 0.025 
Hazardous alcohol consumption 
     
   No 54 (64) 30 (36) 1.00 - - - 
   Yes 13 (72) 5 (28) 0.69 (0.23-2.13) 0.521 - - 
Current OST 
      
   No 33 (73) 12 (27) 1.00 - - - 
   Yes 34 (60) 23 (40) 1.86 (0.80-4.34) 0.151 - - 
Injecting (last month) 
      
   No 16 (59) 11 (41) 1.00 - - - 
   Yes 51 (68) 24 (32) 0.68 (0.28-1.70) 0.413 - - 
Frequency of injecting (last month) 
     
   Never 16 (59) 11 (41) 1.00 - - - 
   Less than daily 34 (71) 14 (29) 0.6 (0.22-1.61) 0.309 - - 
   Daily or greater 17 (63) 10 (37) 0.86 (0.29-2.56) 0.78 - - 
Heroin injecting (last month) 
     
   No 30 (65) 16 (35) 1.00 - - - 
   Yes 37 (66) 19 (34) 0.96 (0.42-2.19) 0.928 - - 
Cocaine injecting (last month) 
     
   No 59 (66) 30 (34) 1.00 - - - 
   Yes 8 (62) 5 (38) 1.23 (0.37-4.08) 0.736 - - 
Amphetamine injecting (last month) 
     
   No 51 (71) 21 (29) 1.00 - - - 
   Yes 16 (53) 14 (47) 2.13 (0.88-5.12) 0.093 - - 
Stimulant injecting (last month) 
    
   No 44 (72) 17 (28) 1.00 - - - 
   Yes 23 (56) 18 (44) 2.03 (0.88-4.66) 0.097 2.43 (1.01-5.85) 0.048 
a 
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